Skip to main content
S&P 5007,764.640.00%DOW51,863.69-0.36%NASDAQ27,244.28+0.45%BTC$86,470.00+0.43%ETH$2,761.37-0.22%GOLD$4,396.20+0.45%OIL$90.03-0.54%
Smart Investors Daily
OG

NYSE · OGN

Organon & Co.

Healthcare · Drug Manufacturers - General

$13.70

Up+$0.02 (+0.15%)

Updated Sep 23, 2026, 2:37 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.91B
P/E ratio
3.82
Dividend yield
2.48%
52-week range
$5.69 – $13.79
Volume
1.37M
Avg. volume
5.64M

Price performance

OGN price history

1M range · 20 trading sessions · Daily adjusted prices

OGN closed at $13.70 after 20 trading sessions, down 0.36% for the selected period.

Last close
$13.70
Period change
-0.36%
Period low
$13.63
Period high
$13.78
Daily close
View OHLC price history
OGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 22, 2026$13.70$13.72$13.68$13.701.37M
Sep 21, 2026$13.70$13.76$13.67$13.683.12M
Sep 18, 2026$13.68$13.70$13.68$13.684.94M
Sep 17, 2026$13.67$13.69$13.66$13.691.26M
Sep 16, 2026$13.65$13.68$13.65$13.672.07M
Sep 15, 2026$13.65$13.68$13.65$13.663.59M
Sep 14, 2026$13.64$13.67$13.64$13.651.25M
Sep 11, 2026$13.65$13.65$13.63$13.641.73M
Sep 10, 2026$13.66$13.66$13.63$13.632.08M
Sep 9, 2026$13.78$13.78$13.635$13.675.56M
Sep 8, 2026$13.77$13.78$13.75$13.751.63M
Sep 4, 2026$13.76$13.78$13.76$13.784.87M
Sep 3, 2026$13.77$13.78$13.725$13.773.92M
Sep 2, 2026$13.77$13.78$13.76$13.773.63M
Sep 1, 2026$13.75$13.785$13.75$13.763.44M
Aug 31, 2026$13.76$13.77$13.75$13.764.05M
Aug 28, 2026$13.76$13.77$13.76$13.762.71M
Aug 27, 2026$13.76$13.77$13.76$13.763.19M
Aug 26, 2026$13.74$13.77$13.74$13.774.15M
Aug 25, 2026$13.74$13.76$13.74$13.753.56M

Latest OGN news

The latest Smart Investors Daily articles mentioning OGN.

Stock researchCompany · Overview

OGN research

Overview

Company profile and research snapshot.

Company profile

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.25
Implied upside
—
Analysts
—
OGN recent ratings
DateFirmRatingTarget
Apr 29, 2026BNP ParibasNeutral—
Apr 28, 2026Piper SandlerNeutral—
Feb 24, 2026BarclaysUnderweight—
Dec 9, 2025BarclaysUnderweight—
Nov 11, 2025JP MorganUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By